Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses

David Ulmert; Andrew J Vickers; Howard I Scher; Charlotte Becker; Peter Iversen; David Frankel; Jens Kristian Jehrbo Jensen; Tine Kold Olesen; Hans Lilja

doi:10.1515/cclm-2011-0967

Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses

David Ulmert, Andrew J Vickers, Howard I Scher, Charlotte Becker, Peter Iversen, David Frankel, Jens Kristian Jehrbo Jensen, Tine Kold Olesen, Hans Lilja

9 Citations (Scopus)

Abstract

The utility of conventional prostate-specific antigen (PSA) measurements in blood for monitoring rapid responses to treatment for prostate cancer is limited because of its slow elimination rate. Prior studies have shown that free PSA (fPSA), intact PSA (iPSA) and human kallikrein-related peptidase 2 (hK2) are eliminated more rapidly after radical prostatectomy. In contrast, all three markers have similarly slow elimination rates after castration induced by gonadotropin-releasing hormone (GnRH) agonists, possibly due to the slow onset of castration. Therefore, we assessed elimination rates of tPSA, fPSA, iPSA and hK2 after rapid induction of castration with degarelix (Firmagon(®)), a novel GnRH antagonist.

Original language	English
Journal	Clinical Chemistry and Laboratory Medicine
Volume	50
Issue number	11
Pages (from-to)	1993-8
Number of pages	6
ISSN	1434-6621
DOIs	https://doi.org/10.1515/cclm-2011-0967
Publication status	Published - 2012

Access to Document

10.1515/cclm-2011-0967

Fingerprint

Dive into the research topics of 'Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses'. Together they form a unique fingerprint.

Cite this

Ulmert, D., Vickers, A. J., Scher, H. I., Becker, C., Iversen, P., Frankel, D., Jensen, J. K. J., Olesen, T. K., & Lilja, H. (2012). Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses. Clinical Chemistry and Laboratory Medicine, 50(11), 1993-8. https://doi.org/10.1515/cclm-2011-0967

Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses. / Ulmert, David; Vickers, Andrew J; Scher, Howard I et al.
In: Clinical Chemistry and Laboratory Medicine, Vol. 50, No. 11, 2012, p. 1993-8.

Research output: Contribution to journal › Journal article › Research › peer-review

Ulmert, D, Vickers, AJ, Scher, HI, Becker, C, Iversen, P, Frankel, D, Jensen, JKJ, Olesen, TK & Lilja, H 2012, 'Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses', Clinical Chemistry and Laboratory Medicine, vol. 50, no. 11, pp. 1993-8. https://doi.org/10.1515/cclm-2011-0967

Ulmert D, Vickers AJ, Scher HI, Becker C, Iversen P, Frankel D et al. Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses. Clinical Chemistry and Laboratory Medicine. 2012;50(11):1993-8. doi: 10.1515/cclm-2011-0967

Ulmert, David ; Vickers, Andrew J ; Scher, Howard I et al. / Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer : potential for rapid monitoring of treatment responses. In: Clinical Chemistry and Laboratory Medicine. 2012 ; Vol. 50, No. 11. pp. 1993-8.

@article{dc6a43216a434f3ab4d6af753a3a7db5,

title = "Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses",

abstract = "The utility of conventional prostate-specific antigen (PSA) measurements in blood for monitoring rapid responses to treatment for prostate cancer is limited because of its slow elimination rate. Prior studies have shown that free PSA (fPSA), intact PSA (iPSA) and human kallikrein-related peptidase 2 (hK2) are eliminated more rapidly after radical prostatectomy. In contrast, all three markers have similarly slow elimination rates after castration induced by gonadotropin-releasing hormone (GnRH) agonists, possibly due to the slow onset of castration. Therefore, we assessed elimination rates of tPSA, fPSA, iPSA and hK2 after rapid induction of castration with degarelix (Firmagon({\textregistered})), a novel GnRH antagonist.",

author = "David Ulmert and Vickers, {Andrew J} and Scher, {Howard I} and Charlotte Becker and Peter Iversen and David Frankel and Jensen, {Jens Kristian Jehrbo} and Olesen, {Tine Kold} and Hans Lilja",

year = "2012",

doi = "10.1515/cclm-2011-0967",

language = "English",

volume = "50",

pages = "1993--8",

journal = "Clinical Chemistry and Laboratory Medicine",

issn = "1434-6621",

publisher = "Walter/de Gruyter GmbH & Co. KG",

number = "11",

}

TY - JOUR

T1 - Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer

T2 - potential for rapid monitoring of treatment responses

AU - Ulmert, David

AU - Vickers, Andrew J

AU - Scher, Howard I

AU - Becker, Charlotte

AU - Iversen, Peter

AU - Frankel, David

AU - Jensen, Jens Kristian Jehrbo

AU - Olesen, Tine Kold

AU - Lilja, Hans

PY - 2012

Y1 - 2012

N2 - The utility of conventional prostate-specific antigen (PSA) measurements in blood for monitoring rapid responses to treatment for prostate cancer is limited because of its slow elimination rate. Prior studies have shown that free PSA (fPSA), intact PSA (iPSA) and human kallikrein-related peptidase 2 (hK2) are eliminated more rapidly after radical prostatectomy. In contrast, all three markers have similarly slow elimination rates after castration induced by gonadotropin-releasing hormone (GnRH) agonists, possibly due to the slow onset of castration. Therefore, we assessed elimination rates of tPSA, fPSA, iPSA and hK2 after rapid induction of castration with degarelix (Firmagon(®)), a novel GnRH antagonist.

AB - The utility of conventional prostate-specific antigen (PSA) measurements in blood for monitoring rapid responses to treatment for prostate cancer is limited because of its slow elimination rate. Prior studies have shown that free PSA (fPSA), intact PSA (iPSA) and human kallikrein-related peptidase 2 (hK2) are eliminated more rapidly after radical prostatectomy. In contrast, all three markers have similarly slow elimination rates after castration induced by gonadotropin-releasing hormone (GnRH) agonists, possibly due to the slow onset of castration. Therefore, we assessed elimination rates of tPSA, fPSA, iPSA and hK2 after rapid induction of castration with degarelix (Firmagon(®)), a novel GnRH antagonist.

U2 - 10.1515/cclm-2011-0967

DO - 10.1515/cclm-2011-0967

M3 - Journal article

C2 - 22718641

SN - 1434-6621

VL - 50

SP - 1993

EP - 1998

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

IS - 11

ER -